Experimental data from osteoblast and osteosarcoma models have shown that loss or inactivation of WWOX leads to aberrant RUNX2 activity, contributing to oncogenic processes through deregulated osteogenic signaling [4, 6]. This evidence concerns the gene WWOX and osteosarcoma.